Skytrofa
Payments companies reported to CMS as associated with Skytrofa. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Skytrofa, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Skytrofa
These are the largest totals companies reported as associated with Skytrofa. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Aristides Maniatis | Centennial, CO | Pediatric Endocrinology | $173,424.77 |
| Toni Kim | Sandy Springs, GA | Pediatric Endocrinology | $124,199.79 |
| Joshua Yang | Orlando, FL | Pediatric Endocrinology | $120,275.22 |
| Philippe Backeljauw | Cincinnati, OH | Pediatric Endocrinology | $102,105.37 |
| Nidhi Gupta | Franklin, TN | Pediatric Endocrinology | $74,584.20 |
| Kent Reifschneider | Norfolk, VA | Pediatric Endocrinology | $53,154.14 |
| Alan Rogol | Charlottesville, VA | Pediatrics | $48,695.16 |
| Asheesh Dewan | Las Vegas, NV | Pediatric Endocrinology | $29,740.37 |
| Jose Gamez-Godoy | Edinburg, TX | Pediatric Endocrinology | $27,219.88 |
| Eileen Baez - Irizarry | Phoenix, AZ | Pediatric Endocrinology | $22,323.63 |
Prescribed Skytrofa?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.